H9N2 Avian Flu Vaccine Paired with Adjuvant Provokes Strong Human Immune Response at Low Doses

When combined with an immune-boosting substance called an adjuvant, low doses of an experimental vaccine against a strain of avian influenza (H9N2) provoked a strong antibody response in human volunteers, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The clinical trial of 96 adults was conducted at the NIAID-supported Viral Respiratory Pathogens Research Unit at Baylor College of Medicine, Houston, and was led by Robert L. Atmar, MD. The results are now online in Clinical Infectious Diseases.

The results of this clinical trial add to the growing body of information demonstrating the potential value of adjuvanted avian influenza vaccines, says NIAID director Anthony S. Fauci, MD. An adjuvant is a substance that is added to a vaccine to boost the bodys immune response to the vaccines antigen. In the event of an influenza pandemic, adjuvanted vaccines could provide a way to extend a limited vaccine supply to more people, he adds.

In 1999, two children in Hong Kong became infected with H9N2, a strain of avian influenza that had not previously been detected in humans. Humans have little or no natural immunity to a virus such as H9N2 or the more deadly H5N1 avian influenza that historically has circulated only in birds. If H9N2 or H5N1 were to acquire the ability to spread easily from person to person, an influenza pandemic could result, health experts say.

In 2004, NIAID directed Novartis Vaccines and Diagnostics (formerly Chiron Corporation) to produce 40,000 doses of an experimental H9N2 vaccine at its vaccine manufacturing facility in Siena, Italy. Some of the vaccines were formulated with Novartiss MF59 adjuvant.

Atmar and his colleagues tested the vaccines in volunteers aged 18 to 34 in this Phase I clinical trial. Phase I vaccine trials assess candidate vaccines safety and ability to stimulate an immune response, and are not designed to determine whether the vaccine would prevent infection by naturally occurring virus. The researchers vaccinated 48 volunteers with non-adjuvanted H9N2 vaccine (made from inactivated virus) at one of four dosages 3.75, 7.5, 15 or 30 micrograms. An additional 48 volunteers received MF59-adjuvanted vaccine at one of the same four dosages. Volunteers were vaccinated twice, with inoculations spaced 28 days apart.

An avian flu vaccine, like the seasonal flu vaccine, should stimulate antibodies, which help ward off infection if the vaccinated person later encounters the flu virus. In general, the higher the level of antibodies made in response to a vaccine, the more protective the vaccine is, Atmar notes. In our trial, a single inoculation of adjuvant-containing H9N2 vaccine, even at the lowest dosage, generated a good antibody response, says Atmar. By comparison, the seasonal flu vaccine contains 15 micrograms each of three different circulating flu strains much higher than the 3.75 micrograms of H9N2 flu virus contained in the lowest dose vaccine tested in this trial. Furthermore, he adds, a single dose of the adjuvanted H9N2 vaccine was as good as two doses of the vaccine without adjuvant.

Currently, MF59 is licensed for use as a vaccine adjuvant in Europe but not in the United States. The results of this trial, says Atmar, suggest that MF59 is deserving of further study.

NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism.

Reference: RL Atmar et al. Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clinical Infectious Diseases 10.1086/508174; 2006.

National Institutes of Health (NIH)